A Dose-block Randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 After Oral Administration in Healthy Adult Volunteers
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Rocacetrapib (Primary)
- Indications Dyslipidaemias
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
Most Recent Events
- 10 Sep 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jun 2014 New trial record